CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company dedicated to developing innovative treatments for psychiatric and neurodegenerative diseases such as depression, Parkinson’s disease, Alzheimer’s disease, and certain orphan conditions. Recognizing the limitations of current therapies—such as delayed efficacy, significant side effects, and minimal impact on disease progression—CuraSen is pioneering a novel approach. The company focuses on restoring key functionalities lost early in neurodegeneration and aging by targeting inadequate adrenergic stimulus in the brain. With an experienced team in neuroscience, adrenergic pharmacology, chemistry, and clinical development, CuraSen is advancing treatments that activate key brain receptors to address unmet medical needs. Backed by premier investors like New Leaf Venture Partners, Longitude Capital, and the Alzheimer’s Drug Discovery Foundation, CuraSen is committed to transforming the therapeutic landscape for these challenging diseases.